Literature DB >> 11376205

Fulminant liver failure during interferon beta treatment of multiple sclerosis.

E M Yoshida1, S L Rasmussen, U P Steinbrecher, S R Erb, C H Scudamore, S W Chung, J J Oger, S A Hashimoto.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11376205     DOI： 10.1212/wnl.56.10.1416

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  10 in total

Review 1.  Type I IFN-mediated regulation of IL-1 production in inflammatory disorders.

Authors:  Kristina Ludigs; Valeriy Parfenov; Renaud A Du Pasquier; Greta Guarda
Journal:  Cell Mol Life Sci       Date:  2012-04-24       Impact factor: 9.261

2.  Acute hepatitis secondary to interferon beta-1a in multiple sclerosis.

Authors:  V Christopher; N Scolding; R T Przemioslo
Journal:  J Neurol       Date:  2005-03-08       Impact factor: 4.849

3.  Development of autoimmune hepatitis type 1 after pulsed methylprednisolone therapy for multiple sclerosis: a case report.

Authors:  Atsushi Takahashi; Yukiko Kanno; Yuta Takahashi; Natsumi Sakamoto; Kyoko Monoe; Hironobu Saito; Kazumichi Abe; Junko Yokokawa; Atsushi Irisawa; Hiromasa Ohira
Journal:  World J Gastroenterol       Date:  2008-09-21       Impact factor: 5.742

Review 4.  Hepatic injury, liver monitoring and the beta-interferons for multiple sclerosis.

Authors:  Helen Tremlett; Joel Oger
Journal:  J Neurol       Date:  2004-11       Impact factor: 4.849

Review 5.  US FDA-approved disease-modifying treatments for multiple sclerosis: review of adverse effect profiles.

Authors:  Steven L Galetta; Clyde Markowitz
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

6.  Hepatic reactions during treatment of multiple sclerosis with interferon-beta-1a: incidence and clinical significance.

Authors:  Gordon S Francis; Yves Grumser; Enrica Alteri; Alain Micaleff; Fanny O'Brien; Jonathan Alsop; Margaretha Stam Moraga; Neil Kaplowitz
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

7.  An Autopsy Case of Fulminant Hepatitis in a Patient with Multiple Sclerosis Treated by Interferon-Beta-1a.

Authors:  Yuichi Yamazaki; Aya Suzuki; Kimitoshi Hirayanagi; Yusuke Tsukagoshi; Ryota Uehara; Kazuhiko Horiguchi; Tatsuya Ohyama; Takuya Tomaru; Norio Horiguchi; Sumihito Nobusawa; Hayato Ikota; Ken Sato; Satoru Kakizaki; Motoyasu Kusano; Yoshio Ikeda; Hideaki Yokoo; Masanobu Yamada
Journal:  Intern Med       Date:  2017-07-15       Impact factor: 1.271

8.  Early stage and long term treatment of multiple sclerosis with interferon-beta.

Authors:  Angela Applebee; Hillel Panitch
Journal:  Biologics       Date:  2009-07-13

9.  Presentation and outcomes with clinically apparent interferon beta hepatotoxicity.

Authors:  Robert J Fontana; Paul Hayashi; Herbert L Bonkovsky; David E Kleiner; Sweta Kochhar; Jiezhun Gu; Marwan Ghabril
Journal:  Dig Dis Sci       Date:  2013-02-02       Impact factor: 3.487

Review 10.  The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review.

Authors:  Marco Biolato; Assunta Bianco; Matteo Lucchini; Antonio Gasbarrini; Massimiliano Mirabella; Antonio Grieco
Journal:  CNS Drugs       Date:  2021-07-28       Impact factor: 5.749
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.